Symposium 19: Secretagogues: sulfonylureas and incretins

Authors

  • Víctor Commendatore Hospital San Martín de Paraná, Entre Ríos, Argentina

DOI:

https://doi.org/10.47196/diab.v54i3Sup.353

Keywords:

drugs, diabetes mellitus type 2

Abstract

Symposium 19: Pharmacological treatment: what's new?

Secretagogues: sulfonylureas and incretins

SUs and DPP4i have gained a place in current diabetes mellitus (DM) therapy.

Regarding SUs, referring to glimepiride, gliclazide and glipizide, since glimepiride is lately not recommended, we will leave aside its qualities in the treatment of neonatal DM and MODY3, to focus on its place within the approach schemes of the DM2, answering some fundamental questions.

Author Biography

Víctor Commendatore, Hospital San Martín de Paraná, Entre Ríos, Argentina

Specialist in Endocrinology, Master in Diabetes; Head of the Endocrinology, Diabetes and Nutrition Service

References

-1- Amod A. The Place of Sulfonylureas in Guidelines: Why Are There Differences? Diabetes Ther. 2020 Jun;11(Suppl 1):5-14. DOI: 10.1007/s13300-020-00811-3. Epub 2020 Apr 22..

-2- Rosenstock J, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019 Sep 19;322(12):1155–66. DOI: 10.1001/jama.2019.13772.

-3- Taylor OM, Lam C. The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review. Curr Ther Res Clin Exp. 2020 Jul 25;93:100596. doi: 10.1016/j.curtheres.2020.100596.

-4- Pitocco D, Tartaglione L, Viti L, Di Leo M, Pontecorvi A, Caputo S. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons? Diabetes Res Clin Pract. 2020 May;163:108162. doi: 10.1016/j.diabres.2020.108162.

Downloads

Published

2023-01-10

How to Cite

Commendatore, V. (2023). Symposium 19: Secretagogues: sulfonylureas and incretins. Journal of the Argentine Society of Diabetes, 54(3Sup), 77–77. https://doi.org/10.47196/diab.v54i3Sup.353

Issue

Vol. 54 No. 3Sup (2020): September/December 2020

Section

Symposiums part 5

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)